Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For patients:
- People diagnosed with intermediate-risk acute myeloid leukemia (a type of blood cancer) for the first time, where the disease is in complete remission at the molecular level (meaning no detectable cancer cells using sensitive tests)
- People diagnosed with high-risk acute myeloid leukemia for the first time, where the disease is in complete remission at the molecular level, and who are waiting for a stem cell transplant from an unrelated donor
- People with a general health and functioning score of 70 or above on standard medical rating scales (meaning they are able to care for themselves and carry out normal activity, at least partly)
- People who have given written agreement to take part in the trial
For donors (the family member donating cells):
- A family member who is a half-matched (haploidentical) donor
- A donor who meets standard medical guidelines for donating cells through an apheresis procedure (a process of collecting specific cells from the blood)
- A donor who has given written agreement to take part
Who may not be able to join:
For patients:
- People who have an active infection that is not under control
- People with serious liver problems, where certain liver enzyme levels in the blood are five times or more above the normal range for their age
- People who test positive for HIV
For donors:
- People who are pregnant
- People who test positive for HIV, hepatitis B, or hepatitis C
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Olga Aleinikova, MD, Prof, Belarussian Research Center for Pediatric Oncology, Hematology and Immunology
Phone: +375296341853
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Relapse-free survival (RFS); Overall survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.